Immunogenic Cell Death in Hematological Malignancy Therapy

Although the curative effect of hematological malignancies has been improved in recent years, relapse or drug resistance of hematological malignancies will eventually recur. Furthermore, the microenvironment disorder is an important mechanism in the pathogenesis of hematological malignancies. Immunogenic cell death (ICD) is a unique mechanism of regulated cell death (RCD) that triggers an intact antigen-specific adaptive immune response by firing a set of danger signals or damage-associated molecular patterns (DAMPs), which is an immunotherapeutic modality with the potential for the treatment of hematological malignancies. This review summarizes the existing knowledge about the induction of ICD in hematological malignancies and the current research on combining ICD inducers with other treatment strategies for hematological malignancies.

Automated summary

Although the treatment efficacy for hematological malignancies has improved, relapse or drug resistance remains a challenge. Microenvironment disorder plays a significant role in the pathogenesis of these malignancies. Immunogenic cell death (ICD) is a unique mechanism that triggers an adaptive immune response through danger signals or damage-associated molecular patterns, making it a potential immunotherapeutic approach for hematological malignancies. This review provides an overview of ICD induction in hematological malignancies and current research on combining ICD inducers with other treatment strategies.